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ABSTRACT
Background and study aims: To assess the cost-effective-
ness of introducing endoscopic treatment based on radiof-
requency ablation plus endoscopic mucosal resection 
in selected patients into the standard of care of Barrett’s 
esophagus patients with high-grade dysplasia or low-grade 
dysplasia in Spain.
Methods: The disease evolution was modeled via a 
semi-Markov model. The treatment strategies compared 
included endoscopic treatment based on radiofrequency 
ablation plus endoscopic mucosal resection and the Stan-
dard of Care (esophagectomy or palliative chemoradiother-
apy according to disease status for high-grade dysplasia 
and endoscopic surveillance for low-grade dysplasia). Effi-
cacy rates, transition probabilities and utility values were 
obtained from the literature. Clinical management patterns 
and resource use were modeled according to Spanish clini-
cal expert opinion. Costs were expressed in euros (€) from 
2016 reflecting the Spanish National Health System per-
spective. Sensitivity analyses were performed to assess the 
robustness of the model.
Results: With respect to the Spanish Standard of Care, 
endoscopic treatment based on radiofrequency ablation 
plus endoscopic mucosal resection was a dominant strat-
egy for high-grade dysplasia patients. When a willing-
ness-to-pay threshold of €30,000 per quality-adjusted life-
years gained was considered, this was cost-effective for 
low-grade dysplasia patients (€12,865 per quality-adjusted 
life-years gained). The sensitivity analyses supported the 
base case analysis results and pointed towards the main 
drivers of uncertainty in the model.
Conclusions: From a health care decision-maker, endoscop-
ic treatment based on radiofrequency ablation plus endo-
scopic mucosal resection is the intervention of choice for 
dysplasic Barrett’s esophagus patients in Spain.
Key words: Cost-benefit analysis. Barrett esophagus. 
Esophageal neoplasms. Catheter ablation. Standard of care. 
Endoscopy. Esophagectomy. Spain.
INTRODUCTION
Barrett’s esophagus (BE) is a metaplastic or abnormal change 
in the cells that line the lower portion of the esophagus, 
resulting in the replacement of normal stratified squamous 
epithelium with simple columnar epithelium with globet 
cells (1). The definition and diagnostic criteria of BE and the 
histopathological stage classification is difficult and varies 
worldwide (2,3). However, there is a majority agreement that 
a pathology report should state the presence or absence of 
intestinal metaplasia (IM) as well as the endoscopic presence 
of columnar mucosa of the esophagus (2). Malignant degen-
eration is thought to occur via a multistep morphological 
pathway from IM to low-grade dysplasia (LGD), high-grade 
dysplasia (HGD) and eventually esophageal adenocarcino-
ma (EAC) (2). Once established, BE does not regress despite 
the control of gastroesophageal reflux disease symptoms (4) 
and is considered to be a precancerous condition. The evolu-
tionary stages of the disease may provide an opportunity to 
intervene prior to the development of EAC (5).
The risk of progression of BE within the different stages 
is also difficult to accurately predict (2,3,6,7). In general, 
the risk of progression to EAC is lower in BE patients with 
IM and increases progressively in BE patients with LGD 
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and HGD (2,3,6). The rate of progression of non-dysplas-
tic Barrett esophagus (NDBE) to EAC is estimated to be 
between 0.1 and 0.5% per year, respectively (8,9). Howev-
er, in patients with dysplastic Barrett esophagus, the risk of 
progress to EAC is reported to increase to 10% per year (in 
patients with HGD) (10).
The choice of treatment depends on the presence and grade of 
dysplasia (3,7,10-12). Guidelines agree that endoscopic muco-
sal resection (EMR) is the optimum therapeutic alternative for 
early EAC and for HGD with visible, nodular areas. Endoscopic 
radiofrequency ablation (RFA) is used for flat HGD (3,7,10-12) 
and esophagectomy is reserved only for patients with EAC 
that extends into the submucosa (7,11). Consensus documents 
also recommend endoscopic ablation for BE patients with 
LGD (2,3,6,7), while the optimum treatment of IM remains 
unclear and further research is required (2,3,11,12).
BE has a significant economic impact on healthcare sys-
tems due to the high prevalence and long-term cost of dis-
ease management. The annual treatment costs for BE are 
estimated at €328 million for a total of 540,131 BE patients 
diagnosed in Spain (13). The economic burden of BE is 
expected to rise, due to the increasing incidence over recent 
decades (14). The direct costs associated with BE include 
the costs of the physician and hospital visits, the cost of 
endoscopic procedures and possible complications, such 
as stricture or perforation and the cost of anti-neoplastic 
medication for unresectable or persistent EAC (13). 
There are no formal treatment guidelines for dysplasic BE 
intervention in Spain. According to clinical expert opin-
ion, the most frequently employed standard of care (SoC) 
during recent years was esophagectomy for HGD and endo-
scopic surveillance for LGD. Recently, RFA has emerged 
as an alternative treatment for BE in Spain, although no 
assessment has been made of its economic value.
Due to the long-term economic challenges of BE, the uncer-
tainty with regard to the relative value of alternative health-
care interventions for its management and budget con-
straints in the Spanish National Health Service (NHS); the 
objective of this study was to assess the cost-effectiveness 
of the inclusion of RFA in the SoC of dysplastic BE in Spain. 
MATERIAL AND METHODS 
Study design 
A literature review was carried out in order to identify phar-
macoeconomic analyses of dysplastic BE and obtain the 
main inputs of the model. A panel of three Spanish clinical 
experts in digestive endoscopy participated in the mod-
el design, input selection, model assumptions, reporting 
and interpretation of results. The study was performed by 
means of a structured questionnaire and telephone inter-
views. A final consensus on the study outcomes was agreed 
via a teleconference.
Patients 
The study population included two hypothetical cohorts 
of Spanish patients diagnosed with either LGD or HGD. 
According to the evidence published in the main clinical 
trials that have evaluated RFA, the mean age of the two 
cohorts was set at 65 years (range 55-75 years) (1,14,15). 
Treatment strategies 
According to the clinical experts, the SoC for HGD was 
esophagectomy and endoscopic surveillance once per 
year for LGD. EMR was thought to precede RFA in 15% of 
patients (for visible nodular areas). For editing purposes, 
this procedure is referred to as endoscopic treatment based 
on radiofrequency ablation plus endoscopic mucosal resec-
tion (RFA-EMR) in the manuscript.
The frequency of endoscopic surveillance was agreed upon 
by the panel of clinical experts. The frequencies were once 
every 3 years for cured patients with a history of BE, once 
every year for patients with LGD, once every 6 months for 
patients with HGD and once every 3 months for patients 
with EAC. Patients aged > 75 years were thought to have 
suspended regular endoscopic surveillance due to the low 
cost differential between the treatment strategies assessed 
in the model. 
Type of analysis
A cost-effectiveness model was built using Microsoft Excel 
2013 to compare the costs and effects of RFA-EMR versus 
SoC. The cost-effectiveness of RFA-EMR compared to SoC 
alone for BE with HGD and LGD was assessed using the 
incremental cost-effectiveness ratio (ICER). Both the cost 
and effectiveness generated by these alternatives were 
compared as follows:
CostRFA-EMR and CostSoC represent the cost associated with 
RFA-EMR and SoC, respectively. EffectivenessRFA-EMR and 
EffectivenessSoC represent the clinical consequences in terms 
of life-years gained (LYG), quality-adjusted life years (QALY) 
gained and esophagectomy or EAC cases prevented. The 
ICER was expressed as the incremental cost per QALY gained 
of RFA-EMR compared to SoC. The number of patients that 
needed to be treated (NNT) to prevent one esophagectomy, 
one course of chemoradiotherapy or one case of EAC was 
estimated. The associated cost savings were also estimated.
The analysis was performed from a Spanish NHS perspec-
tive, considering only direct medical costs with a time horizon 
of 15 years. A discount rate of 3% was applied to future costs 
and outcomes in accordance with Spanish guidelines (16).
Pharmacoeconomic model
A semi-Markov model was used to simulate patient tran-
sitions between six health states that reflected disease 
progression and patient survival during the study period. 
Health states were defined according to the presence and 
degree of dysplasia as follows: cured with a history of BE 
(patients with neither dysplasia nor IM after successful 
treatment with RFA or esophagectomy), NDBE (patients 
 CostRFA-EMR – CostSoC
ICER =
 EffectivenessRFA-EMR – EffectivenessSoC
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without dysplasia but with IM), LGD, HGD, EAC and death. 
Figure 1 shows a simplified diagram of the model.
The patient cohort entered the model in either the LGD 
or HGD health state. Depending on the transition proba-
bilities reflected by the natural course of the disease and 
the efficacy of the interventions, at the end of each cycle 
(1 year) the patients remain in the same health state or 
transition to another health state. Conservatively, it was 
assumed that patients with a history of BE that were cured 
after esophagectomy would have no risk of recurrence, 
while patients with a history of BE that were cured after 
RFA would have the same disease progression rates as 
NDBE patients. However, more optimistic scenarios were 
considered after RFA. The major complications and mor-
tality associated with the diagnosis and treatment of EAC, 
together with age-related mortality were also included (17). 
Clinical inputs
The efficacy of the treatment strategies, defined as the 
complete eradication of intestinal metaplasia (CE-IM) or 
complete eradication of dysplasia (CE-D) and the transi-
tions between health states, were based on previously pub-
lished economic models, randomized controlled trials and 
systematic reviews (Table 1).
Use of resources and costs
The direct medical costs considered in the model included 
drugs costs, procedures cost, follow-up costs and treat-
ment complications costs. Clinical management patterns 
and the use of resources associated with the management 
of patients with BE in Spain were consulted and validat-
ed by the panel of three clinical experts. Unit costs were 
obtained from national healthcare cost databases (18,19) 
and all costs were expressed in Euros from 2016 (Table 2). 
Quality of life
Utility values were used to represent impact in terms of 
quality of life associated with a particular health state on a 
scale of 0 (death) to 1 (perfect health). The assignment of 
utility values to each health state of the model allowed the 
calculation of the QALYs associated with each alternative. 
As data on the quality of life were not collected in clinical 
trials, utility values were obtained from the literature. The 
model used the utility values published by Gerson et al. 
(2007) (20) that were adjusted to the utility of the Spanish 
population aged between 65-69 years (0.88) (21) (Table 1).
Sensitivity analysis
In order to assess the influence of parameter uncertain-
ty on the results and the robustness of the model, the 
main assumptions of the model were varied over a wide 
range of values in a series of one-way sensitivity analy-
ses (OWSA). The horizon modelled was varied between 5 
and 25 years and the discount rate applied to costs and 
effects varied between 0% and 5%. The ranges used for the 
remaining parameters were based on published data. In the 
absence of published data, baseline rates were increased 
Fig. 1. Transition state diagram (NDBE: non-dysplastic Barrett esophagus; LGD: low-grade dysplasia; HGD: high-grade 
dysplasia; EAC: esophageal adenocarcinoma; RFA-EMR: endoscopic treatment based on radiofrequency ablation 
plus endoscopic mucosal resection; EMR: endoscopic mucosal resection; BE: Barrett’s esophagus; CE-IM: complete 
eradication of intestinal metaplasia; CE-D: complete eradication of dysplasia).
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and decreased by 25% and were adjusted according to the 
consensus of the clinical expert panel.
A structural sensitivity analysis was performed, that consid-
ered a more optimistic scenario in which patients with a histo-
ry of BE that were cured after RFA-EMR were thought to pres-
ent a lower rate of disease progression than NDBE patients. 
Probabilistic sensitivity analyses (PSA) were performed using 
a Monte Carlo simulation in which distributions for specific 
model input variables (gamma for costs and utility values, 
beta for eradication, stricture and perforation rates and trian-
gular for transition probabilities) were assigned and 1,000 iter-
ations were performed. The results of the sensitivity analyses 
were stratified by thresholds for the dominance and cost-ef-
fectiveness within the commonly accepted willingness-to-pay 
(WTP) threshold in Spain (€30,000/QALY) (22).
Table 1. Model inputs: efficacy and safety of treatment alternatives, transition probabilities (natural history of Barrett’s 
esophagus) and model utilities
Parameter Baseline value Range Source
Efficacy data
RFA in LGD*
CE-IM = 88.20% 79.38% 95.59%
(14)CE-D with residual IM†= 4.41% -
Remain in the same health state (no success)‡ = 7.39% 16.21% 0.00%
RFA in HGD*
CE-IM = 74.00% 66.60% 92.86%
(1)CE-D with residual IM2 = 7.14% -
Remain in the same health state (no success)‡ = 18.86% 26.26% 0.00%
Esophagectomy in HGD 
or resectable EAC§
CE-IM = 80.00% 60.00% 90.00%
(29)Mortality rate = 5.00% 2.50% 10.00%
Remain in the same health state (no success)‡ = 15.00% -
Safety data
Stenosis rate (RFA) 5.00% 3.75% 6.25% (30)
Stenosis rate (EMR) 22.30% 16.73% 27.88% (31)
Perforation rate (RFA) 0.00% 0.00% 0.07% (30,37)
Perforation rate (EMR) 1.20% 0.90% 1.50% (31)
Transition 
probabilities
NDBE to LGD 5.00% 3.75% 6.25%
(27,29)
NDBE to HGD 1.00% 0.75% 1.25%
NDBE to EAC 0.50% 0.38% 0.63%
LGD to NDBE 63.00% 47.25% 78.75%
LGD to HGD 5.00% 3.75% 6.25%
LGD to EAC 2.50% 1.88% 3.13%
HGD to NDBE 1.00% 0.75% 1.25%
HGD to LGD 7.00% 5.25% 8.75%
HGD to EAC 5.50% 4.13% 6.88%
EAC (unresectable) to 
death
90.00% 67.50% 100.00%
Utility score for each 
health state‖




NDBE 0.80 0.78 0.82
LGD 0.75 0.73 0.76
HGD 0.68 0.66 0.69
EAC 0.59 0.57 0.61
Death 0.00 0.00 0.00
Disutility due to 
procedures‖
Esophagectomy 0.10 0.05 0.20
(37)
Chemoradiotherapy 0.05 0.03 0.10
RFA: radiofrequency ablation; LGD: low-grade dysplasia; CE-IM: complete eradication of intestinal metaplasia; CE-D: complete eradication of dysplasia; IM: intestinal metaplasia; HGD: high-grade 
dysplasia; EAC: esophageal adenocarcinoma; EMR: endoscopic mucosal resection; NDBE: non-dysplastic Barrett esophagus; BE: Barrett esophagus. *It was assumed that after RFA, regardless of 
its success, that patients would not undergo any further RFA treatment. †CE-D with residual IM: the result of the subtraction between CE-D and CE-IM (NDBE). ‡Estimated from a difference of 100% 
and the probabilities of transit to other stages. §It was assumed that after esophagectomy in HGD or resectable EAC, patients would not undergo any further esophagectomy and would initiate 
endoscopic surveillance. ‖Range values were estimated from a 25% variation in the difference in terms of utility of consecutive health states. 
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Table 2. Model inputs: costs
Unit costs (€, 2016)
Baseline value
Range Source
Unit cost Resource use
Drugs
Chemoradiotherapy €19,494.65 €14,620.99 € 24,368.31 (18,19)
 Radiotherapy: 50 Gy €118.24 per day 25 days / 2 cycles - (18)
 Chemotherapy: ECF* €116.93 per cycle 4 cycles - (18,19)
 Administration† €156.13 per day 21 days / 4 cycles - (18)
Procedures
Esophagectomy €28,047.88 €21,035.91 €35,059.98
(18)
RFA €9,524.02 €7,143.02 €11,905.03
 Halo 90 €1,500.00 2.00 - Medtronic 
Ibérica, S.A. Halo 360 €2,500.00 1.00 -
 Specialist visit €82.61 3.00 -
(18)
 EGD €1,258.73 3.00 -
EMR €1,959.20 €1,469.40 €2,449.00
 Material €617.86 1.00 -
 Specialist visit €82.61 1.00 -
EGD €1,258.73 1.00 -
Follow-up
Endoscopic surveillance €1,341.34 €1,006.01 €1,676.68
(18)
 Specialist visit €82.61 1.00 -
 EGD €1,258.73 1.00 -
Post- esophagectomy, 1st year €3,397.04 €2,547.78 €4,246.29
 EGD €1,258.73 1.00 -
 Specialist visit €82.61 4.00 -
 Blood test €74.16 4.00 -
 CAT scan €184.12 1.00 -
 Hospitalization €156.13 8.50 -
Post-esophagectomy, 2nd year €497.66 €373.25 €622.08
 Specialist visit €82.61 2.0 -
 Blood test €74.16 2.0 -
 CAT scan €184.12 1.0 -
Treatment 
complications
Stricture €4,024.02 €3,018.02 €5,030.03
(18)
 EGD €1,258.73 3.00 -
 Specialist visit €82.61 3.00 -
Perforation €10,921.88 €8,191.41 €13,652.36
 Surgical‡ €31,444.92 30.00% -
 OVESCO clip €1,400.00 35.00% -
 Prosthesis €2,852.60 35.00% -
Gy: gray; RFA: radiofrequency ablation; EMR: endoscopic mucosal resection; EGD: esophagogastroduodenoscopy; CAT: computerized axial tomography. *Chemotherapy with ECF includes 50 mg/m2 
on day 1 of epirubicin, plus 60 mg/m2 on day 1 of cisplatin, plus 200 mg/m2/day of 5-fluorouracil. †Oncological hospital day stay. ‡When the perforation was resolved by surgical intervention, it was 
assumed that an equivalent use of resources such as esophagectomy plus the 1st year of follow-up post-esophagectomy would be required.
RESULTS
The following results were obtained for the different 
treatment strategies in the two patient cohorts (HGD 
and LGD): LYG for each health state; cost of treatment; 
QALYs gained and ICER; number of esophagectomies, 
chemoradiotherapy and EAC cases prevented; NNT to 
prevent one esophagectomy, one chemoradiotherapy 
treatment, one EAC, or one endoscopic surveillance vis-
it; and costs saved per patient-year via the prevention of 
esophagectomies, chemoradiotherapy and/or endoscopic 
surveillance visits.
J. M. Esteban et al.




RFA-EMR in the SoC of BE patients with HGD
This strategy avoided 62.1% of esophagectomies, 62.2% 
of chemoradiotherapy courses and 8.1% of endoscopic 
surveillance visits. This resulted in savings of €1,402 per 
patient-year which was equivalent to €21,023 per patient 
over the time horizon of the study. After introducing RFA-
EMR into the SoC of BE patients with HGD, the NNT in 
order to prevent one esophagectomy, one chemoradiother-
apy course or one endoscopic surveillance visit was 1.61, 
27.48 and 2.80, respectively. The cost-effectiveness analysis 
showed that introducing RFA into the SoC of BE patients 
with HGD would be a dominant therapeutic strategy due 
to its lower cost (€-11,430 per patient) and the greater LYG 
and QALY gained compared with SoC alone (0.67 LYG and 
1.23 QALY gained per patient) (Table 3).
RFA-EMR in the SoC of BE patients with LGD
The introduction of RFA-EMR into the SoC of BE patients 
with LGD compared with SoC alone would provide an addi-
tional 0.10 LYG and 0.56 QALY gained per patient. RFA-EMR 
reduced the risk of esophagectomy, chemoradiotherapy 
and EAC by 20.0%, 23.9% and 20.7%, respectively. This 
resulted in savings of €199.0 per patient-year, equivalent 
to €2,985 per patient over the time horizon of the study. 
After adding RFA-EMR to the SoC of BE patients with LGD, 
the NNT in order to prevent one esophagectomy, one EAC, 
or one endoscopic surveillance visit was 17.96, 46.43 and 
1.20, respectively. Nevertheless, the cost-effectiveness anal-
ysis showed that introducing RFA-EMR into the SoC of BE 
patients with LGD would result in an incremental cost of 
€8,087 per patient over the time horizon of the study. This 
resulted in an ICER of €12,865 per QALY gained (Table 3).
Sensitivity analysis
RFA-EMR in the SoC of BE patients with HGD
The OWSA results for the HGD cohort showed that the 
greatest variations in the ICER resulted from changes in 
the time horizon of the model, the disutility and the cost 
associated with esophagectomy together with the cost of 
RFA. Despite this, the resulting ICER remained dominant in 
all OWSA scenarios (Fig. 2A). In addition, PSA confirmed 
these results. After 1,000 simulations, 100% of cases sup-
ported the dominance of adopting RFA-EMR into the SoC 
of HGD patients (Fig. 2B). 
RFA-EMR in the SoC of BE patients with LGD
The cost-effectiveness of adding RFA-EMR into the SoC of 
LGD patients would be more favorable (with a lower ICER 
and greater avoided costs) when a minimum improvement 
in disease progression after CE-IM was considered. When 
considering that CE-IM after RFA-EMR in LGD patients 
would provide a 20% reduction in disease progression com-
pared with the natural course of NDBE; the base case ICER 
would also decrease from €12,865 to €10,122 per QALY 
gained and the percentage of esophagectomies, chemora-
diotherapy courses or EAC cases avoided would rise. These 
clinical benefits would lead to an additional cost saving 
of €889 per patient (a 29.8% relative increase) (data not 
shown).
OWSA results for the LGD cohort showed that the greatest 
variations in the ICER resulted from changes in the cost of 
RFA, the utility score of cured patients with a history of BE, 
the time horizon of the model and the age at diagnosis. 
However, none of the resulting scenarios surpassed the 
commonly-accepted WTP threshold in Spain (Fig. 3A) (22). 
The PSA confirmed these results. After 1,000 simulations, 
100% of cases supported the cost-effectiveness of adopting 
RFA-EMR into the SoC of LGD patients and remained below 
the commonly-accepted WTP threshold for adopting new 
health technologies in Spain (22) (Fig. 3B).
DISCUSSION
There is increasing debate regarding the use of resources to 
implement preventive strategies to reduce the rising costs 
of healthcare associated with EAC, one of the fastest grow-
ing cancers in the last three decades (23,24). In this regard, 
economic analysis can be useful for the quantitative esti-
mation of the resources needed to implement competing 
clinical management strategies for BE patients under uncer-
tain conditions. This study is the first economic evaluation 
of RFA (RFA-EMR in Spain) for the treatment of different 
stages of BE according to the clinical practice in Spain. 
There is a general agreement with regard to the efficien-
cy of RFA for the management of HGD patients (5,10,25). 
In this base-case analysis, RFA-EMR dominated over SoC 
alone in these patients. These results are in line with other 
cost-effectiveness analyses that concluded that RFA-EMR 
was a valid alternative treatment choice for HGD (26-30).
To date, the subgroup of patients with LGD is the main 
area of controversy with regard to the ablative treatment 
of BE (23). However, recent evidence has confirmed the 
long-term efficacy and safety of RFA for the treatment of 
LGD (14,31,32) and this has been acknowledged by health 
technology evaluation agencies (3). The analysis presented 
here used a different pattern of clinical practice but was 
similar to studies carried out in the USA (27,29) and Europe 
(30,33). These studies have shown that RFA-EMR with SoC 
was a cost-effective strategy compared to SoC alone in BE 
patients with LGD.
Some authors suggest that ablation might be preferable 
in patients with LGD if endoscopic surveillance could be 
reduced or even discontinued after a successful eradica-
tion (23,27,29). In our analysis, RFA-EMR remained cost-ef-
fective even when endoscopic surveillance was main-
tained after CE-IM and, overall, reduced the total number 
of surveillance sessions required due to a lower proba-
bility of progression to health states that require a more 
intensive follow-up. As further post-ablation data becomes 
available, it is likely that there will be more discussion of 
the optimal management strategy.
The analysis presented here has some limitations. Due to 
the current lack of Spanish guidelines for the diagnosis and 
treatment of patients with BE, it was estimated that the 
Economic evaluation of endoscopic radiofrequency ablation for the treatment of dysplastic Barrett’s esophagus in Spain
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management of BE in Spain would not differ significantly 
from the European recommendations (3,11,12,25). Conse-
quently, in order to ensure that the SoC considered was 
representative of Spanish clinical practice, a panel of clini-
cal experts was consulted in order to provide and validate 
the main use of resources and the current SoC for HGD and 
LGD patients. Recent international guidelines have started 
to recommend endoscopic ablative therapy not only for 
BE patients with HGD, but also for LGD (3,6,7,12,34). How-
ever in Spain, ablative treatment is still only available in 
a few specialized centers and surgery remains the most 
common therapeutic choice when patients with BE develop 
non-nodular HGD. Nevertheless, other valid treatment alter-
natives, such as endoscopic submucosal dissection should 
be further evaluated as their use becomes more frequent in 
clinical practice. On the other hand, concomitant treatment 
alternatives such as proton pump inhibitors (35,36) were 
not considered in this analysis as they implied a limited 
Fig. 2. Sensitivity analyses results of introducing RFA-EMR into the SoC of BE patients with HGD. A. One-way 
deterministic sensitivity analysis. Tornado diagram. B. Probabilistic sensitivity analysis. Incremental cost-effectiveness 
plane (RFA-EMR: endoscopic treatment based on radiofrequency ablation plus endoscopic mucosal resection; SoC: 
standard of care; BE: Barrett’s esophagus; HGD: high-grade dysplasia; CE-IM: complete eradication of intestinal 
metaplasia; ICER: incremental cost-effectiveness ratio; QALY: quality-adjusted life year).
Fig. 3. Sensitivity analyses results of introducing RFA-EMR into the SoC of BE patients with LGD. A. One-way 
deterministic sensitivity analysis. Tornado diagram. B. Probabilistic sensitivity analysis. Incremental cost-effectiveness 
plane (RFA-EMR: endoscopic treatment based on radiofrequency ablation plus endoscopic mucosal resection; SoC: 
standard of care; BE: Barrett’s esophagus; LGD: low-grade dysplasia; NDBE: non-dysplastic Barrett esophagus; HGD: 
high-grade dysplasia; EAC: esophageal adenocarcinoma; ICER: incremental cost-effectiveness ratio; QALY: quality-
adjusted life year).
Economic evaluation of endoscopic radiofrequency ablation for the treatment of dysplastic Barrett’s esophagus in Spain
REV ESP ENFERM DIG 2018:110(3):145-154 
DOI: 10.17235/reed.2017.5087/2017
153
cost that was equal for all interventions compared in this 
study. Moreover, the analysis was based on a mathematical 
model and therefore has limitations due to the variability 
in the data sources included in the model and the assump-
tions applied in their absence. However, these are inherent 
issues of disease modeling and extensive sensitivity anal-
yses were performed.
The additional LYG in the EAC health state when newly diag-
nosed HGD patients are intervened with RFA-EMR instead 
of esophagectomy, favors esophagectomy and might indi-
cate that the use of RFA-EMR would lead to a longer peri-
od of time with cancer. In fact, our results derive from the 
assumption that patients that underwent esophagectomy 
fully recovered from BE and had no risk of progression to 
cancer or mortality due to the esophagectomy or relapsed 
cancer. This does not occur in RFA-EMR treated patients, 
these patients remain at risk of progression to cancer and 
of undergoing an esophagectomy (with an associated risk 
of mortality). Future research should consider study the effi-
cacy of RFA according to the length of BE, as this could help 
identify patients with a higher risk of neoplastic progression 
in whom endoscopic ablation may be more beneficial. This 
information could aid the modeling of the cost-effective-
ness of RFA in NDBE patients, where RFA efficacy is still 
unknown (2,3).
Although ablative therapy followed by endoscopic sur-
veillance has been reported to reduce the recurrence of 
IM (1,15), it is not uncontroversial (30). Consequently, the 
conservative assumption was made that the relapse rates 
of cured patients with a history of BE after RFA-EMR and 
the disease progression rates of NDBE patients would be 
the same. This assumption also balances the decision not 
to include the possibility of buried crypts after RFA or the 
possibility of a misdiagnosis. However, more optimistic sce-
narios were considered in the structural sensitivity analysis 
and these showed that the base case clinical and economic 
results could improve when a minimal durability effect was 
considered after ablative therapy.
Critical parameters have been identified and these should 
guide further research. According to the sensitivity analysis 
results, the difference in terms of utilities between non-EAC 
vs. EAC health states was one of the main drivers of the 
cost-effectiveness analysis. Together with the lack of specific 
utilities for Spanish BE patients, this may be considered 
as an additional study limitation. Further research on the 
quality of life of patients with BE would add value to these 
findings.
Overall, our analysis indicates that the introduction of RFA-
EMR into the SoC of BE patients diagnosed with HGD or 
LGD results in clinical benefits. On the one hand, it would 
translate into additional LYG and QALYs and on the other 
hand would reduce the use of high-cost invasive treatment 
alternatives for advanced BE. According to the estimated 
NNT, one esophagectomy, which is a highly-invasive proce-
dure associated with a risk of mortality, could be avoided by 
treating 1.61 patients diagnosed with BE and HGD or 17.96 
patients with BE and LGD with an initial RFA-EMR.
Finally, from a healthcare decision-maker perspective, 
when a WTP threshold of €30,000/QALY gained in the 
Spanish setting is considered, the addition of RFA-EMR to 
the SoC would be the intervention of choice for the man-
agement of BE patients with HGD or LGD in the clinical 
practice in Spain.
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